{"id":27856,"date":"2014-08-11T09:52:24","date_gmt":"2014-08-11T13:52:24","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=27856"},"modified":"2014-08-11T09:52:24","modified_gmt":"2014-08-11T13:52:24","slug":"ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856","title":{"rendered":"Ebola vaccine of GlaxoSmithKline plc (ADR) (NYSE:GSK) To Undergone Clinical Trial Soon"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/11\/2014 (wallstreetpr) \u2013\u00a0Ebola Virus has already caused thousands of deaths in all parts of the world, especially in Europe and African countries, but drug makers are yet to find out the vaccine. In amidst of deaths all around the world, reports about <b>GlaxoSmithKline plc (ADR) (NYSE:GSK)<\/b>&#8216;s new vaccine for Ebola can be a motivating factor for all the countries. According to latest reports, the vaccine will go through a clinical <a href=\"http:\/\/www.reuters.com\/article\/2014\/08\/10\/health-ebola-vaccine-idUSL6N0QG0UW20140810?type=companyNews&amp;feedType=RSS&amp;feedName=companyNews\">trial<\/a> very soon.<\/p>\n<p style=\"text-align: justify;\"><b>Damage So Far: <\/b><\/p>\n<p style=\"text-align: justify;\">So far this deadly virus has caused around 1000 deaths in West Africa alone. Other countries have also reported victims of Ebola Virus. If the situation continues for some more time, then researchers from all around the world can start feeling the pressure to find out the solution for Ebola Virus.<\/p>\n<p style=\"text-align: justify;\">Due to the failure of all the major countries to find out any proven solution for Ebola, the World Health Organization has decided to declare it an international health emergency. GSK has developed a vaccine that has got excellent results in animals and its first phase in humans is due. As soon as the company gets approval from the U.S. Food and Drug Administration, it will start working on the next phase.<\/p>\n<p style=\"text-align: justify;\">According to a spokeswoman of GlaxoSmithKline plc (ADR) (NYSE:GSK), &#8220;We are quite hopeful that the next trial will begin in the later part of this year.&#8221; Although U.S. National Institute of Allergy and Infectious Diseases (NIAID) said that the trial will begin by the fourth quarter of 2014. According to reports, even if trial begin in a couple of months&#8217; time, there is no guarantee that Ebola Vaccine will be ready by the end of this year. In any case, scientists will be able to produce a vaccine by the first quarter of next year, provided everything goes according to plans during clinical trials. When reporters asked from a GSK representative about the Ebola Vaccine, &#8220;He said, it&#8217;s still a long way to go so we can&#8217;t commit any date as of now.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/11\/2014 (wallstreetpr) \u2013\u00a0Ebola Virus has already caused thousands of deaths in all parts of the world, especially in Europe and African countries, but [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":27857,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1734,1735],"stock_ticker":[],"class_list":["post-27856","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-glaxosmithkline-plc-adr-nysegsk","tag-nysegsk","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ebola vaccine of GlaxoSmithKline plc (ADR) (NYSE:GSK) To Undergone Clinical Trial Soon - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ebola vaccine of GlaxoSmithKline plc (ADR) (NYSE:GSK) To Undergone Clinical Trial Soon - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/11\/2014 (wallstreetpr) \u2013\u00a0Ebola Virus has already caused thousands of deaths in all parts of the world, especially in Europe and African countries, but [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-11T13:52:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/GlaxoSmithKline-plc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"168\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"Ebola vaccine of GlaxoSmithKline plc (ADR) (NYSE:GSK) To Undergone Clinical Trial Soon\",\"datePublished\":\"2014-08-11T13:52:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856\"},\"wordCount\":349,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/GlaxoSmithKline-plc.jpg\",\"keywords\":[\"GlaxoSmithKline plc (ADR) (NYSE:GSK)\",\"NYSE:GSK\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856\",\"name\":\"Ebola vaccine of GlaxoSmithKline plc (ADR) (NYSE:GSK) To Undergone Clinical Trial Soon - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/GlaxoSmithKline-plc.jpg\",\"datePublished\":\"2014-08-11T13:52:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/GlaxoSmithKline-plc.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/GlaxoSmithKline-plc.jpg\",\"width\":300,\"height\":168},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ebola vaccine of GlaxoSmithKline plc (ADR) (NYSE:GSK) To Undergone Clinical Trial Soon\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ebola vaccine of GlaxoSmithKline plc (ADR) (NYSE:GSK) To Undergone Clinical Trial Soon - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856","og_locale":"en_US","og_type":"article","og_title":"Ebola vaccine of GlaxoSmithKline plc (ADR) (NYSE:GSK) To Undergone Clinical Trial Soon - Wall Street PR","og_description":"Boston, MA 08\/11\/2014 (wallstreetpr) \u2013\u00a0Ebola Virus has already caused thousands of deaths in all parts of the world, especially in Europe and African countries, but [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-11T13:52:24+00:00","og_image":[{"width":300,"height":168,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/GlaxoSmithKline-plc.jpg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"Ebola vaccine of GlaxoSmithKline plc (ADR) (NYSE:GSK) To Undergone Clinical Trial Soon","datePublished":"2014-08-11T13:52:24+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856"},"wordCount":349,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/GlaxoSmithKline-plc.jpg","keywords":["GlaxoSmithKline plc (ADR) (NYSE:GSK)","NYSE:GSK"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856","url":"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856","name":"Ebola vaccine of GlaxoSmithKline plc (ADR) (NYSE:GSK) To Undergone Clinical Trial Soon - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/GlaxoSmithKline-plc.jpg","datePublished":"2014-08-11T13:52:24+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/GlaxoSmithKline-plc.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/GlaxoSmithKline-plc.jpg","width":300,"height":168},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/ebola-vaccine-of-glaxosmithkline-plc-adr-nysegsk-to-undergone-clinical-trial-soon-27856#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Ebola vaccine of GlaxoSmithKline plc (ADR) (NYSE:GSK) To Undergone Clinical Trial Soon"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/27856","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=27856"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/27856\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/27857"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=27856"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=27856"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=27856"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=27856"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}